How the Immune System Fights Cancer: Immunology Explained

The Immune System's War Against Cancer

Every day, the human body produces thousands of cells with genetic mutations that could potentially become cancerous. In most cases, the immune system identifies and eliminates these abnormal cells before they can form tumors — a process called immunosurveillance. Cancer develops when malignant cells evolve mechanisms to evade, suppress, or overwhelm this immune defense. Understanding the complex relationship between the immune system and cancer has led to immunotherapy, one of the most significant advances in cancer treatment in decades.

Immunosurveillance: Finding Cancer Cells

The immune system recognizes cancer cells through abnormal proteins (neoantigens) displayed on their surface. These mutant proteins are presented on MHC class I molecules, flagging the cell as abnormal:

Natural Killer (NK) cells — Detect cells that have downregulated MHC I expression (a common cancer evasion tactic) and kill them without prior sensitization
Cytotoxic T lymphocytes (CD8+ T cells) — Recognize specific tumor antigens via T cell receptors and deliver targeted killing through perforin and granzymes
Dendritic cells — Capture tumor debris, process antigens, and present them to T cells in lymph nodes, initiating adaptive immune responses
Macrophages — Phagocytose cancer cells and release pro-inflammatory cytokines that recruit other immune cells

The Cancer-Immunity Cycle

Step	Process	Key Players
1. Antigen release	Cancer cell death releases neoantigens	Dying tumor cells
2. Antigen presentation	Dendritic cells capture and present antigens	Dendritic cells, MHC molecules
3. T cell priming	T cells are activated in lymph nodes	CD4+ and CD8+ T cells
4. T cell trafficking	Activated T cells travel to the tumor	Chemokines, adhesion molecules
5. Tumor infiltration	T cells penetrate the tumor microenvironment	TILs (tumor-infiltrating lymphocytes)
6. Cancer cell recognition	TCR binds tumor antigen on MHC I	CD8+ T cells
7. Cancer cell killing	Cytotoxic attack destroys the cancer cell	Perforin, granzymes, FasL

How Cancer Evades the Immune System

Tumors that successfully grow have developed sophisticated escape mechanisms:

Evasion Strategy	Mechanism	Effect
Checkpoint exploitation	Express PD-L1 to bind PD-1 on T cells	Inactivates attacking T cells
MHC downregulation	Reduce surface antigen presentation	Become invisible to CD8+ T cells
Immunosuppressive microenvironment	Recruit Tregs, MDSCs; secrete TGF-β, IL-10	Suppresses local immune response
Antigen loss	Stop expressing immunogenic neoantigens	No longer recognized as abnormal
Metabolic competition	Deplete glucose and amino acids locally	Starves T cells of fuel

Immunotherapy: Unleashing the Immune System

Checkpoint Inhibitors

Drugs like pembrolizumab (anti-PD-1), nivolumab (anti-PD-1), and ipilimumab (anti-CTLA-4) release the brakes on T cells by blocking inhibitory checkpoints. These have produced durable responses in melanoma, lung cancer, kidney cancer, and many other tumor types.

CAR-T Cell Therapy

A patient's T cells are genetically engineered to express chimeric antigen receptors targeting specific tumor proteins (e.g., CD19 in blood cancers). These modified cells are expanded in the laboratory and reinfused, producing remarkable complete response rates in previously untreatable leukemias and lymphomas.

Other Approaches

Cancer vaccines — Personalized neoantigen vaccines train the immune system against individual tumor mutations
Oncolytic viruses — Modified viruses selectively infect tumor cells, killing them and triggering immune responses
Bispecific antibodies — Simultaneously bind T cells and tumor cells, creating an artificial immunological synapse
Cytokine therapy — IL-2, interferons boost overall immune activation (though with significant side effects)

Challenges and Future Directions

Immunotherapy works dramatically in some patients but fails in others. Current research focuses on identifying biomarkers that predict response, combining therapies for synergistic effects, overcoming the immunosuppressive tumor microenvironment, and extending benefits to "cold" tumors that lack immune cell infiltration. The convergence of genomics, single-cell analysis, and AI-driven drug design promises increasingly personalized immunotherapy approaches.

This article is for educational purposes only and does not constitute medical advice. Consult an oncologist or healthcare professional for questions about cancer treatment, immunotherapy, or any medical condition.